Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Zacks.com on MSN1d
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical HoldAmgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...
Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib ...
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...
Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...
Amgen (NASDAQ:AMGN – Get Free Report) is expected to be issuing its quarterly earnings data after the market closes on ...
Volume growth of AMGN's key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by ...
Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback